Abingworth LLP, the London-based investment group, has created a new fund to invest in late-stage life science assets that are being developed by two of its portfolio companies under contract with the pharmaceutical industry. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Clinical Research
